For all about
SWOG...Note about our SWOG meetings...
Our public session is on the 12th. It's basically a 5 hour marathon with death by Powerpoint and debate on upcoming trials with the press and industry folks looking in. We actually meet to go through all the stuff the day earlier before the public sees it. I know there are two new PCa trials being considered. For my part we basically get together as PA's during the week. 10 of us that meet to discuss how we are being included in our committees. I am very active in the GU committee and have been getting much support by the Chair Ian Thompson and Co-Chair Nick Vogelzang. Their resume for PCa research includes, Docetaxel (Taxotere), Jevtana, Provenge, Alpharadin (Radium 223), Enzalutimade (Xtandi), Abiraterone Acetate (Zytiga).
If that list sounds familiar it's the top recently released advanced prostate cancer therapeutic drugs. These guys make things happen in research and it's very cool serving in committee with them knowing that they WILL make a difference. Their roles have been as primary investigators, assigning the PI's, designing the trials that have lead to FDA approvals, and designing future trials that will impact prostate cancer therapy once again.
One of the goals at SWOG is two PCa trials per year designed and activated. The time and the complexity of dealing with the NCI, CTEP, independent IRB's, and the FDA, and all of the funders, is an excruciating process. I am very amazed at what goes into releasing a trial to the public. My role is to report on the patient facing information and review the ICF forms so far. Is this a good trial? Will the patient community be adoptive? Does this meet specific needs in research? Ar all questions I get to participate in. I also get to participate in the behind the scenes monthly teleconferences reviewing the trials and the accrual. This is where the rubber meets the road and progress gets reviewed internally.
Nothing super secret but fascinating to a layman like myself. I can name a number of folks here at HW that are very qualified to do this. I'm lucky to have the HW friends as resources. I report on the chatter here when asked and they listen. They are very interested in what gets discussed in the patient communities.
For the record,
Most of the doctors want to see better guidelines and testing tools. SWOG is idle on the AUA guidelines with it's urology members split on new guidelines. Our radiation guys as well. The Medical oncology team members generally seem to agree and believe in screening but also understand the issues with ODOT and want better screening techniques. Again SWOG is idle and does not advocate screening guidelines nor issue any. SWOG has over 4000 oncologists, all on the "high end" of their fields that comprise our researchers. If you've been around PCa a few years the chances are you have heard of many of our researchers.
I serve on two committees and have been volunteering in one other:
GU Committee. This committee is the PCa group. But they also discuss Renal, bladder, and other GU cancers.
Patient Advocate Committee. This is just what it sounds like. PA's getting together to discuss our challenges and how to improve our integration to the primary committees for which we serve on. (Right now it's Myloma, Lung, Pancreatic, GU, Blood Cancers, Breast, Cancer Survival, and Colon.
Imaging Committee. I just walked in to listen and they welcomed me to stay. Still unofficial.
Sadly, Dan Moore, long time UsTOO leader and member of the Cancer Survival Committee, passed away this past couple months ago from cancer (Not PCa). So we are filling that one soon.
Below is the link for SWOG check out the "about
I hope to see some of you in Chicago!
Post Edited (TC-LasVegas) : 8/13/2013 4:01:08 PM (GMT-6)